Regenxbio (RGNX) Operating Expenses (2014 - 2026)
Regenxbio (RGNX) posted quarterly Operating Expenses of $9.6 million for Q4 2025, down 86.82% year-over-year from $72.6 million in Q4 2024, and down 88.35% quarter-over-quarter from $82.1 million in Q3 2025.
Regenxbio (RGNX) Operating Expenses (2014 - 2026) Analysis & Trends
Regenxbio's Operating Expenses history runs 12 years deep, the most recent figure standing at $9.6 million for Q4 2025.
- In Q4 2025, Operating Expenses fell 86.82% year-over-year to $9.6 million; the TTM figure through Dec 2025 stood at $176.2 million (down 44.35% YoY), while the FY2025 annual figure was $32.9 million, down 89.62% from the prior year.
- Operating Expenses for Q4 2025 stood at $9.6 million, down from $82.1 million in the prior quarter.
- The five-year high for Operating Expenses was $97.6 million in Q3 2022, with the low at -$275.7 million in Q4 2022.
- The 5-year median for Operating Expenses is $83.6 million (2021), against an average of $58.6 million.
- The sharpest annual moves came in 2022 and 2023: Operating Expenses sank 424.15% in 2022, then soared 131.23% in 2023.
- Regenxbio's Operating Expenses stood at $85.1 million in 2021, then tumbled by 424.15% to -$275.7 million in 2022, then jumped by 131.23% to $86.1 million in 2023, then decreased by 15.72% to $72.6 million in 2024, then sank by 86.82% to $9.6 million in 2025.
- Business Quant data shows RGNX's Operating Expenses at $9.6 million in Q4 2025, $82.1 million in Q3 2025, and $7.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Regenxbio | 583.35 Mn | 477.83 Mn | 106.98 Mn | 78.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 78.76 Mn |
| Dec 31, 2025 | 9.57 Mn |
| Sep 30, 2025 | 82.14 Mn |
| Jun 30, 2025 | 7.64 Mn |
| Mar 31, 2025 | 76.89 Mn |
| Dec 31, 2024 | 72.58 Mn |
| Sep 30, 2024 | 86.28 Mn |
| Jun 30, 2024 | 78.33 Mn |
| Mar 31, 2024 | 79.49 Mn |
| Dec 31, 2023 | 86.12 Mn |
| Sep 30, 2023 | 93.87 Mn |
| Jun 30, 2023 | 93.09 Mn |
| Mar 31, 2023 | 85.30 Mn |
| Dec 31, 2022 | -275.72 Mn |
| Sep 30, 2022 | 97.56 Mn |
| Jun 30, 2022 | 95.18 Mn |
| Mar 31, 2022 | 93.75 Mn |
| Dec 31, 2021 | 85.06 Mn |
| Sep 30, 2021 | 88.12 Mn |
| Jun 30, 2021 | 74.26 Mn |